Skip to main navigation
  • Newsroom
  • Get in Touch
  • LinkedIn
Editas Medicine logo
  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors
  • Newsroom
  • Get in Touch
  • LinkedIn

Media & Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting Materials
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor FAQs
  • Information Request
  • Contact

Press Releases

Press Releases

Keyword Search

February 25, 2021
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
February 18, 2021
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
February 8, 2021
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer
January 20, 2021
Editas Medicine Announces Pricing of Offering of Common Stock
January 19, 2021
Editas Medicine Announces Offering of Common Stock
January 11, 2021
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
January 11, 2021
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
January 11, 2021
Editas Medicine Announces Transition of Chief Scientific Officer
January 4, 2021
Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

>> Main navigation

  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors

©Copyright 2021 Editas Medicine

>> Footer menu

  • Get in Touch
  • Investors
  • Privacy Policy
  • Terms of Use